- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05374317
Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine
August 7, 2023 updated by: US Army Medical Research Institute of Infectious Diseases
An Exploratory, Pilot Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine
This is an open-label, randomized, exploratory study to evaluate the human immune response to reduced subcutaneous (SQ) dosing of Yellow Fever vaccine compared to the standard FDA approved subcutaneous vaccination dose.
The current dose of the US FDA licensed Yellow Fever vaccine is approximately 55,000 plaque-forming unit(s) (PFU) in 0.5 mL administered SQ.
Using the licensed dosage as standard, investigators are evaluating reduced doses of 1/5th (0.10 mL) and 1/10th (0.05 mL) Yellow Fever vaccine (YF-VAX).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Up to 150 individuals will be screened in order to randomize 90 eligible individuals to one of three groups: Group 1- YF-VAX® standard dose 0.5 mL SQ = 30 subjects; Group 2-0.10 mL (1/5th) SQ = 30 subjects; Group 3-0.05 mL (1/10th) SQ = 30 subjects.
Study Type
Interventional
Enrollment (Actual)
88
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Frederick, Maryland, United States, 21702
- United States Army Medical Research Institute of Infectious Diseases
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Males and Females 18 to 50 years of age.
- In good health, as determined by pertinent medical history, physical examination, vital signs, and clinical safety laboratory evaluations.
- Female of child bearing potential: Has a negative pregnancy test and is willing to use a reliable form of contraception for the duration of the study after vaccination.
- Negative human immunodeficiency virus (HIV) antibody screen, seronegative for hepatitis B surface antigen (HBsAg) and hepatitis C antibody (following HIV and hepatitis testing, subjects will be provided with counseling and referral for health care if any test is positive).
- Ability to comprehend and a willingness to sign an informed consent, which includes the Health Insurance Portability and Accountability Act (HIPAA) Authorization, and a separate consent form for HIV testing.
- Be willing to comply with all follow-up visits, testing, adverse event (AE) reporting, and completion of diary card.
Exclusion Criteria:
- Receipt of any other investigational vaccine or investigational drug within 28 days prior to or after vaccination with YF-VAX® vaccine.
- Have had any known flavivirus disease or receipt of any flavivirus vaccine, licensed or investigational at any time; in addition to any yellow fever vaccine, these include; Japanese Encephalitis (JE), St. Louis Encephalitis, Tick Borne Encephalitis (TBE), West Nile, Dengue, Zika virus
- Anticipates receipt of any other vaccine within 28 days of YF-VAX®. Influenza vaccination will be permitted but not within 14 days of YF-VAX®.
- Acute or chronic medical conditions, or medications that, in the Principal Investigator's (PI) opinion, would impair the subject's ability to respond to vaccination.
- Hypersensitivity to any vaccine, eggs or egg products, or allergy to any component of the YF-VAX® (sorbitol, gelatin) or latex.
- Corticosteroids even ≥20 mg/day of prednisone for ≥ 2 weeks suppresses the immune system. Low-dose corticosteroid topical products and nasal sprays used sporadically (i.e. prn--according to circumstances) are permissible.
- History of immunosuppression, by any cause--primary or acquired immunodeficiencies, transplantation, malignant neoplasm, lymphoma, leukemia, thymoma, myasthenia gravis, radiation, immunosuppressive drugs, including antimetabolites, tumor necrosis factor (TNF)-alpha inhibitors (etanercept), interleukin-1 (IL-1) blocking agents and other monoclonal antibodies targeting immune cells (e.g., rituximab, alemtuzumab, etc), etc.
- Receipt of or anticipates receipt of/or donation of blood or blood products for 2 months after receipt of YF-VAX®. (Note: Blood banks require a minimum 2 week interval between the receipt of this FDA licensed vaccine and blood donations; however because of the blood collections in this study, an interval of 2 months is requested).
- Female: Pregnant (or planning to become pregnant) or breastfeeding for the duration of the study after receipt of YF-VAX®.
- Clinically significant abnormal laboratory tests (generally 2 times the upper limit of normal or as determined by the PI).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard Dose (Group 1)
Yellow Fever vaccine standard dose, 0.5mL.
|
Administered subcutaneously once.
Other Names:
|
Experimental: Fractional dose (Group 2)
Yellow Fever vaccine 1/5th standard dose, 0.1mL.
|
Administered subcutaneously once.
Other Names:
|
Experimental: Fractional dose (Group 3)
Yellow Fever vaccine 1/10th standard dose, 0.05mL.
|
Administered subcutaneously once.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: Up to one year following vaccination.
|
Incidence of Adverse Events of fractional doses vs standard dose of YF-VAX as determined by subject diary and clinical history and physical examination.
The incidence of solicited and unsolicited adverse events will be analyzed.
|
Up to one year following vaccination.
|
Neutralizing Antibody Response
Time Frame: Up to one year following vaccination.
|
Compare the neutralizing antibody response rate and mean of each ARM as determined by PRNT obtained at several time points.
Fractional doses will be compared to the standard dose of YF-VAX.
The primary data point is post vaccination day 28.
|
Up to one year following vaccination.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Viremia
Time Frame: First 14 days following vaccination.
|
Compare the incidence and level of viremia and mean viral load by RT-PCR (copies/mL) of fractional doses vs standard dose.
|
First 14 days following vaccination.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Phillip R Pittman, M.D., M.P.H., US Army Medical Research Institute of Infectious Diseases
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Campi-Azevedo AC, de Almeida Estevam P, Coelho-Dos-Reis JG, Peruhype-Magalhaes V, Villela-Rezende G, Quaresma PF, Maia Mde L, Farias RH, Camacho LA, Freire Mda S, Galler R, Yamamura AM, Almeida LF, Lima SM, Nogueira RM, Silva Sa GR, Hokama DA, de Carvalho R, Freire RA, Filho EP, Leal Mda L, Homma A, Teixeira-Carvalho A, Martins RM, Martins-Filho OA. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis. 2014 Jul 15;14:391. doi: 10.1186/1471-2334-14-391.
- Martins RM, Maia Mde L, Farias RH, Camacho LA, Freire MS, Galler R, Yamamura AM, Almeida LF, Lima SM, Nogueira RM, Sa GR, Hokama DA, de Carvalho R, Freire RA, Pereira Filho E, Leal Mda L, Homma A. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother. 2013 Apr;9(4):879-88. doi: 10.4161/hv.22982. Epub 2013 Jan 30.
- Wu JT, Peak CM, Leung GM, Lipsitch M. Fractional dosing of yellow fever vaccine to extend supply: a modelling study. Lancet. 2016 Dec 10;388(10062):2904-2911. doi: 10.1016/S0140-6736(16)31838-4. Epub 2016 Nov 10.
- Casey RM, Harris JB, Ahuka-Mundeke S, Dixon MG, Kizito GM, Nsele PM, Umutesi G, Laven J, Kosoy O, Paluku G, Gueye AS, Hyde TB, Ewetola R, Sheria GKM, Muyembe-Tamfum JJ, Staples JE. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report. N Engl J Med. 2019 Aug 1;381(5):444-454. doi: 10.1056/NEJMoa1710430. Epub 2018 Feb 14.
- Monath TP, Woodall JP, Gubler DJ, Yuill TM, Mackenzie JS, Martins RM, Reiter P, Heymann DL. Yellow fever vaccine supply: a possible solution. Lancet. 2016 Apr 16;387(10028):1599-600. doi: 10.1016/S0140-6736(16)30195-7. Epub 2016 Apr 14. No abstract available. Erratum In: Lancet. 2016 Apr 30;387(10030):1816.
- Calisher CH, Woodall JP. Yellow Fever-More a Policy and Planning Problem than a Biological One. Emerg Infect Dis. 2016 Oct;22(10):1859-60. doi: 10.3201/eid2210.160875. Epub 2016 Oct 15. No abstract available.
- Elachola H, Ditekemena J, Zhuo J, Gozzer E, Marchesini P, Rahman M, Sow S, Kattan RF, Memish ZA. Yellow fever outbreaks, vaccine shortages and the Hajj and Olympics: call for global vigilance. Lancet. 2016 Sep 17;388(10050):1155. doi: 10.1016/S0140-6736(16)31546-X. Epub 2016 Sep 5. No abstract available.
- Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS One. 2008 Apr 23;3(4):e1993. doi: 10.1371/journal.pone.0001993.
- Slifka MK, Leung DY, Hammarlund E, Raue HP, Simpson EL, Tofte S, Baig-Lewis S, David G, Lynn H, Woolson R, Hata T, Milgrom H, Hanifin J. Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis. J Allergy Clin Immunol. 2014 Feb;133(2):439-47. doi: 10.1016/j.jaci.2013.10.037. Epub 2013 Dec 10.
- Visser LG, Roukens AH. Modelling a way out of yellow fever. Lancet. 2016 Dec 10;388(10062):2847-2848. doi: 10.1016/S0140-6736(16)31330-7. Epub 2016 Nov 10. No abstract available.
- Yellow fever vaccine: WHO position on the use of fractional doses - June 2017. Wkly Epidemiol Rec. 2017 Jun 23;92(25):345-50. No abstract available. English, French.
- Roukens AHE, Visser LG. Fractional-dose yellow fever vaccination: an expert review. J Travel Med. 2019 Sep 2;26(6):taz024. doi: 10.1093/jtm/taz024.
- Hepburn MJ, Kortepeter MG, Pittman PR, Boudreau EF, Mangiafico JA, Buck PA, Norris SL, Anderson EL. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine. 2006 Apr 5;24(15):2843-9. doi: 10.1016/j.vaccine.2005.12.055. Epub 2006 Jan 18.
- Vasconcelos PF, Monath TP. Yellow Fever Remains a Potential Threat to Public Health. Vector Borne Zoonotic Dis. 2016 Aug;16(8):566-7. doi: 10.1089/vbz.2016.2031. Epub 2016 Jul 11.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 7, 2021
Primary Completion (Actual)
November 2, 2022
Study Completion (Actual)
November 2, 2022
Study Registration Dates
First Submitted
March 28, 2022
First Submitted That Met QC Criteria
May 9, 2022
First Posted (Actual)
May 16, 2022
Study Record Updates
Last Update Posted (Actual)
August 14, 2023
Last Update Submitted That Met QC Criteria
August 7, 2023
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FY19-26
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Yellow Fever Vaccination Reaction
-
University of AarhusMartin TolstrupEnrolling by invitationHealthy | Cytotoxicity | Yellow Fever Vaccination ReactionDenmark
-
CerbaXpertNot yet recruiting
-
PT Bio FarmaDr. Soetomo General HospitalCompleted
-
China National Biotec Group Company LimitedPeking University; Hubei Provincial Center for Disease Control and Prevention; Shaanxi Provincial Center for Disease Control and Prevention and other collaboratorsCompletedTo Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPVVaccination | Reaction - VaccineChina
-
University of Auckland, New ZealandCompletedVaccinationNew Zealand
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingYellow Fever (Healthy Volunteers)United States
-
Tysana Pte LtdCompletedTreatment of Acute Yellow Fever Virus InfectionSingapore
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Wellcome TrustUnknownYellow Fever VaccineBrazil
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Completed
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Ministry of Health, BrazilActive, not recruitingImmunity | Yellow Fever VaccineBrazil
Clinical Trials on Yellow Fever Vaccine
-
Leiden University Medical CenterThe International Society of Travel MedicineRecruiting
-
London School of Hygiene and Tropical MedicineNot yet recruitingYellow Fever
-
EpicentreKenya Medical Research InstituteCompletedYellow FeverUganda, Kenya
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Ministry of Health, BrazilActive, not recruitingImmunity | Yellow Fever VaccineBrazil
-
Emory UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes...Recruiting
-
Sanofi Pasteur, a Sanofi CompanyCompletedYellow Fever (Healthy Volunteers)United States
-
University of Sao Paulo General HospitalCompletedRheumatoid Arthritis | Systemic Sclerosis | Granulomatosis With Polyangiitis | Juvenile Idiopathic Arthritis | Sjogren's Syndrome | Takayasu Arteritis | Spondyloarthritis | Juvenile Dermatomyositis | Mixed Connective Tissue Disease | Systemic Lupus | Inflammatory MyopathyBrazil
-
Centers for Disease Control and PreventionMRC/UVRI and LSHTM Uganda Research Unit; Ministry of Health, Uganda; Infectious...Unknown
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingYellow Fever (Healthy Volunteers)United States
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingStudy on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and AsiaYellow FeverGermany, France, Finland, Singapore, Spain, Thailand